Figure S2 – Cartoon representation of the ABL1 kinase domain in complex with the five ATP-competitive inhibitors currently approved for the treatment of CML and with the allosteric inhibitor asciminib. (A–E) Imatinib, nilotinib and ponatinib are type 2 inhibitors and bind to the inactive conformation of the kinase. Dasatinib and bosutinib are type 1 inhibitors and bind to the active conformation of the kinase. (F) ABL1 in complex with asciminib (ABL001 or GNF-5; indicated with an arrow) and nilotinib. See text for details on binding modes. Images obtained with the web-based 3D viewer NGL (PDB entries: 2HYY [imatinib]; 3CS9 [nilotinib]; 2GQG [dasatinib]; 3VE4 [bosutinib]; 3OXZ [ponatinib]; 5MO4 [asciminib and nilotinib]).